Articles from TCGX Acquisition Corp.

TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, today announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named “TriGemX Bio, Inc.” (the “Combined Company”) and is expected to trade on Nasdaq under the new ticker symbol "TGEM".

TCGX Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 8,625,000 Class A ordinary shares at a price of $10.00 per share, including the 1,125,000 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The Class A ordinary shares are listed on The Nasdaq Capital Market (“Nasdaq”) and began trading under the ticker symbol “TCGX” as of August 5, 2026.

TCGX Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 7,500,000 Class A ordinary shares at a price of $10.00 per share. Unlike certain other special purpose acquisition company initial public offerings, investors in this offering will not receive warrants that would become exercisable following completion of the Company’s initial business combination. The Class A ordinary shares will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “TCGX” beginning August 5, 2026. The offering is expected to close on August 6, 2026, subject to customary closing conditions.